Why a bad cholesterol protein also makes your arteries inflamed
PCSK9 stimulates Syk, PKCδ, and NF-κB, leading to atherosclerosis progression independently of LDL receptor
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
PCSK9 doesn't just raise bad cholesterol—it also directly tells your immune cells to start a fire inside your arteries, making plaques worse. A protein called CAP1 is its helper. Blocking their handshake stops the fire better than current drugs.
Surprising Findings
PCSK9 drives inflammation and plaque growth even in LDL receptor-deficient mice.
For years, PCSK9 was thought to only cause heart disease by raising LDL. This study proves it has a direct, cholesterol-independent inflammatory role—rewriting textbook knowledge.
Practical Takeaways
Ask your doctor for a PCSK9 blood test if you have heart disease or high inflammation markers (like CRP) despite low LDL.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
PCSK9 doesn't just raise bad cholesterol—it also directly tells your immune cells to start a fire inside your arteries, making plaques worse. A protein called CAP1 is its helper. Blocking their handshake stops the fire better than current drugs.
Surprising Findings
PCSK9 drives inflammation and plaque growth even in LDL receptor-deficient mice.
For years, PCSK9 was thought to only cause heart disease by raising LDL. This study proves it has a direct, cholesterol-independent inflammatory role—rewriting textbook knowledge.
Practical Takeaways
Ask your doctor for a PCSK9 blood test if you have heart disease or high inflammation markers (like CRP) despite low LDL.
Publication
Journal
Nature Communications
Year
2024
Authors
Dasom Shin, Soungchan Kim, Hwan Lee, Hyun-Chae Lee, Jaewon Lee, Hyun-woo Park, Mina Fukai, EunByule Choi, Subin Choi, Bon-Jun Koo, Jihoon Yu, Gyurae No, Sung Cho, Chan Woo Kim, Dohyun Han, H. Jang, Hyo-Soo Kim
Related Content
Claims (6)
Elevated low-density lipoprotein (LDL) cholesterol directly drives atherosclerosis and increases cardiovascular disease risk.
People with heart disease have higher levels of PCSK9 in their blood, and that’s linked to higher activity of inflammation proteins in their immune cells — even when their cholesterol is low from taking statins.
A new drug called CAP1-hFc that blocks PCSK9 from sticking to CAP1 works better at reducing inflammation in immune cells than current PCSK9 drugs like evolocumab, which only lower cholesterol.
PCSK9 doesn’t just cause inflammation — it also tricks immune cells into making more PCSK9, creating a cycle that keeps the inflammation going in artery plaques.
PCSK9, a protein in the blood, sticks to another protein called CAP1 on immune cells, which turns on a chain reaction that makes the cells more inflamed and sticky, even if cholesterol levels are normal — this can worsen artery plaque.